Business Context and Reporting Period
This Form 8-K filing by Iveda Solutions, Inc. (IVDA) reports a material definitive agreement entered into on August 9, 2022. The company, incorporated in Nevada and headquartered in Mesa, Arizona, announced a private placement of securities that closed on August 11, 2022.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $5,000,000.
- Securities Issued:
- 1,100,000 shares of Common Stock at $1.52 per share.
- 3,289,474 Common Warrants (exercise price: $1.40; term: 5.5 years).
- 2,189,474 Pre-Funded Warrants (exercise price: $0.0001).
- Placement Agent Fees: 7.0% of gross proceeds payable to Maxim Group LLC, plus reimbursement of expenses and legal fees.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement and a Registration Rights Agreement. The Registration Rights Agreement requires the company to file a registration statement by August 24, 2022, and have it declared effective within 45 days of closing (or 75 days if a full SEC review occurs).
Liquidated Damages Provision: If the company fails to meet specific filing or effectiveness deadlines, it must pay investors 2.0% of their aggregate subscription amount as partial liquidated damages until the event is cured.
Outlook, Risks, and Contingencies
- Regulatory Risk: The securities were sold under Regulation D exemptions and are not registered. Investors are restricted from reselling until a registration statement is effective or Rule 144 exemptions apply.
- Dilution Risk: The issuance of common stock and warrants will increase the total share count, potentially diluting existing shareholders.
- Contingency: The company's ability to avoid liquidated damages payments is contingent on timely SEC filing and effectiveness of the registration statement.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7% placement fee and offering expenses.
- Confirm the filing date and effectiveness status of the Registration Statement referenced in the Registration Rights Agreement.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for additional covenants or restrictions.
- Assess the impact of the new share issuance and warrant exercises on the company's fully diluted share count.